DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 financial results and provided a corporate update.
Recent Highlights and Anticipated Milestones:
- Presented novel preclinical data at SITC 2023 Annual Meeting demonstrating that its CoStimulatory Antigen Receptor (CoStAR) enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells
- Publication of ITIL-306 manuscript in Frontiers in Immunology (https://www.frontiersin.org/articles/10.3389/fimmu.2023.1256491/full), demonstrating that CoStAR enhances T cell activity and augments tumor reactivity of TILs in preclinical studies
- Initial data from ITIL-306-202, a Phase 1 clinical trial of ITIL-306 in non-small cell lung cancer, anticipated in 2024
- Cash runway expected beyond 2026
Third Quarter 2023 Financial and Operating Results:
As of September 30, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $184.5 million, which consisted of $9.1 million in cash and cash equivalents, $1.0 million in restricted cash and $174.3 million in marketable securities, compared to $260.9 million in cash, cash equivalents and marketable securities as of December 31, 2022, consisting of $43.7 million in cash and cash equivalents and $217.2 million in marketable securities. Instil expects that its cash, cash equivalents and marketable securities as of September 30, 2023 will enable it to fund its operating plan beyond 2026.
Research and development expenses were $8.5 million and $37.6 million for the three and nine months ended September 30, 2023, respectively, compared to $39.7 million and $120.3 million for the three and nine months ended September 30, 2022, respectively.
General and administrative expenses were $11.9 million and $36.7 million for the three and nine months ended September 30, 2023, respectively, compared to $17.0 million and $49.3 million for the three and nine months ended September 30, 2022, respectively.
Restructuring and impairment charges were $46.3 million and $71.8 million for the three and nine months ended September 30, 2023, respectively. There were no restructuring and impairment charges for the three and nine months ended September 30, 2022.
INSTIL BIO, INC.
SELECTED FINANCIAL DATA
Selected Consolidated Balance Sheet Data
(Unaudited; in thousands)
| September 30, 2023 | December 31, 2022 | ||||||
| Cash, cash equivalents, restricted cash and marketable securities | $ | 184,461 | $ | 260,920 | |||
| Total assets | $ | 340,272 | $ | 482,128 | |||
| Total liabilities | $ | 106,248 | $ | 118,523 | |||
| Total stockholders’ equity | $ | 234,024 | $ | 363,605 | |||
Consolidated Statements of Operations
(Unaudited; in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 8,492 | $ | 39,660 | $ | 37,621 | $ | 120,334 | |||||||
| General and administrative | 11,941 | 16,989 | 36,681 | 49,325 | |||||||||||
| Restructuring and impairment charges | 46,283 | — | 71,847 | — | |||||||||||
| Total operating expenses | 66,716 | 56,649 | 146,149 | �� | 169,659 | ||||||||||
| Loss from operations | (66,716 | ) | (56,649 | ) | (146,149 | ) | (169,659 | ) | |||||||
| Interest income | 2,313 | 1,276 | 6,671 | 1,859 | |||||||||||
| Interest expense | (2,003 | ) | (807 | ) | (3,229 | ) | (1,138 | ) | |||||||
| Other expense, net | (1,026 | ) | (415 | ) | (455 | ) | (1,863 | ) | |||||||
| Loss before income tax benefit | (67,432 | ) | (56,595 | ) | (143,162 | ) | (170,801 | ) | |||||||
| Income tax benefit | — | 371 | — | 1,468 | |||||||||||
| Net loss | $ | (67,432 | ) | $ | (56,224 | ) | $ | (143,162 | ) | $ | (169,333 | ) | |||
| Net loss per share, basic and diluted | $ | (0.52 | ) | $ | (0.43 | ) | $ | (1.10 | ) | $ | (1.31 | ) | |||
| Weighted-average shares used in computing net loss per share, basic and diluted | 130,079,097 | 129,680,217 | 130,079,097 | 129,391,225 | |||||||||||
Note Regarding Use of Non-GAAP Financial Measures
In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and building and construction in progress impairment expense. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.
INSTIL BIO, INC.
Reconciliation of GAAP to Non-GAAP Net Loss
(Unaudited; in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net loss | $ | (67,432 | ) | $ | (56,224 | ) | $ | (143,162 | ) | $ | (169,333 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense | 4,670 | 7,982 | 13,613 | 23,798 | |||||||||||
| Building and construction work in progress impairment | 41,542 | — | 41,542 | — | |||||||||||
| Non-GAAP net loss | $ | (21,220 | ) | $ | (48,242 | ) | $ | (88,007 | ) | $ | (145,535 | ) | |||
| Net loss per share, basic and diluted | $ | (0.52 | ) | $ | (0.43 | ) | $ | (1.10 | ) | $ | (1.31 | ) | |||
| Adjustments: | |||||||||||||||
| Non-cash stock-based compensation expense per share | 0.04 | 0.06 | 0.10 | 0.18 | |||||||||||
| Building and construction work in progress impairment | 0.32 | — | 0.32 | — | |||||||||||
| Non-GAAP net loss per share, basic and diluted* | $ | (0.16 | ) | $ | (0.37 | ) | $ | (0.68 | ) | $ | (1.13 | ) | |||
| Weighted-average shares outstanding, basic and diluted | 130,079,097 | 129,680,217 | 130,079,097 | 129,391,225 | |||||||||||
* Non-GAAP net loss per share, basic and diluted may not total due to rounding.
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing TIL therapies for the treatment of patients with cancer. Instil has assembled an accomplished management team with a successful track record in the research, development and manufacture of cell therapies. Using its proprietary and optimized manufacturing processes at its in-house manufacturing facility, Instil is developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR™, platform, including ITIL-306, a next-generation, genetically-engineered TIL therapy using the CoStAR platform, for solid tumors. For more information visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “future,” “intends,” “plans,” “potential,” “projects,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the therapeutic potential of our product candidates, our research, development and regulatory plans for our product candidates, including the timing of our ongoing and potential future clinical trials and studies and the availability and presentation of data therefrom, including our expectations concerning our ITIL-306-202 clinical trial, the potential for us to make submissions concerning, and for our product candidates to receive, regulatory approval from the FDA, MHRA or equivalent foreign regulatory agencies and whether, if approved, our product candidates will be successfully distributed and marketed, our expectations regarding Instil's cash runway, capital position, resources, and balance sheet, and the potential impact thereof on our development of ITIL-306, and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming cell therapy product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating, enrolling, reporting data from or completing clinical studies, as well as the risks that results obtained in clinical trials to date may not be indicative of results obtained in ongoing or future trials and that Instil’s product candidates may otherwise not be effective treatments in their planned indications; macroeconomic conditions, including as a result of the conflicts in Ukraine and in the Middle East, interest rates, inflation, bank failures and other factors, which could materially and adversely affect Instil’s business and operations, including Instil's ability to timely initiate, enroll and complete its ongoing and future clinical trials; the time-consuming and uncertain regulatory approval process; risks inherent in manufacturing and testing of cell therapy products and the risk that Instil’s manufacturing process improvements do not ultimately result in enhancements to its product candidates; the sufficiency of Instil’s cash resources, and other risks and uncertainties affecting Instil and its development programs, including those discussed in the section titled “Risk Factors” Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 available on the SEC’s website at www.sec.gov, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 to be filed with the SEC. Additional information will be made available in other filings that we make from time to time with the SEC. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and we disclaim any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
